Nanomedicine & Targeted Delivery

Research |

Polymeric Nanoparticles as Therapeutic Platforms

The nanotechnology as a basic and applied science has uncovered a universe of creative possibilities, impacting almost all aspect of society. Our research attempts to generate advanced therapeutic strategies based on polymeric nanoparticles for the precise delivery of drugs. Since early stages of the preclinical drug development, including the fundamental understanding and interactions of nanoparticles and the life sciences, our group is also focused on the study of pharmacological and toxicological effects of nanoparticles in the physiological and/or pathological conditions. The innovative structure and composition of our nanotherapeutics formulations include the use of novel biomaterials and targeting molecules that support its smart performance and precise organ/tissue delivery. 

 

 

Drug Delivery based on Microparticles Technology

The use of polymeric microparticles as controlled release technology provide a broad spectrum of therapeutic applications leading to the sustained release of drugs over long periods of time.

Our goal in this field is to develop innovative microtechnology systems based on novel biodegradable and biocompatible polymers suitable for the encapsulation and controlled release of antibiotics, chemotherapeutics and others molecules via intramuscular, oral and pulmonary delivery.

 

 

Novel Biomaterials for Nanotherapeutics

Polymer science is the key of current and future endeavor of drug delivery systems. Several parameter such as loading capacity, stability and the drug release mechanisms depend on the polymeric matrix of formulations. Our aim in this field is 

to develop novel biocompatible materials for the advancement of field of nanotherapeutics.

 

Funding |

Current Research Support

  • Principal Investigator, Fondecyt Regular N° 1201147 (2020-2023).

  • Co-Investigator, Fondecyt Regular N° 1181408 (2018-2020).

  • Main Research of Basal Grant Nº AFB180001, CEDENNA (Nanobiomedicine, L6), CONICYT (2020 - 2023, III Phase).

  • Co-Investigator Nucleus-UNAB 2018 (2018-2020).

  • Research Associate of European Union’s Horizon 2020 Research and Innovation Program under the Marie Sklodowsks-Curie Grant Agreement Nº 734801 (2017 - 2021).

  • Co-Sponsor of Postdoctoral FONDECYT Funding Nº 3180250 (2018 - 20120).​​

National |

Collaborators

Dora Altbir, Ph.D.

Center for Development of Nanoscience and Nanotechnology

Faculty of Science

University of Santiago

Santiago – Chile

Carmen Gloria Feijoo, Ph.D.

Laboratory of Immunology in fishes

Faculty of Life Sciences

Universidad Andres Bello

Santiago – Chile

Flavia Zacconi, Ph.D.

Laboratory of Design and Organic Synthesis

Faculty of Chemistry

Pontifical Catholic University of Chile

Santiago, Chile

Claudio Cabello/Verrugio, Ph.D.
Laboratory of Muscle Pathology, Fragility and Aging

Faculty of Life Sciences

Universidad Andres Bello

Santiago – Chile

Iván Palomo, Ph.D.

Thrombosis Research Center

Faculty of Health Sciences

University of Talca

Talca – Chile

International |

Collaborators

Omid Farokhzad, MD.

Center for Nanomedicine – Farokhzad Lab

Brigham and Women's Hospital – Harvard Medical School. 

Boston, USA

 

Jinjun Shi, Ph.D.

Center for Nanomedicine

Brigham and Women's Hospital – Harvard Medical School. 

Boston, USA

Won IL Choi, Ph.D.

Center for Convergence Bioceramic Materials, Convergence R&D Division

Korea Institute of Ceramic Engineering and Technology (KICET)

Seoul, Korea

Nazila Kamaly, Ph.D.

Molecular Science Research Hub

Imperial College London

London, UK

Basit Yameen Ph.D.

Department Of Chemistry & Chemical Engineering

LUMS University

Lahore, Pakistan

 

Carolina Salvador-Morales, Ph.D.

Laboratory of Nanotechnology and Nanomedicine

George Mason University 

Fairfax, VA, USA

Proudly collaborating with

Laboratory of Nanomedicine and Targeted Delivery · Contact Us

Av. Lircay s/n, Universidad de Talca |Talca, Chile